GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » 12-1 Month Momentum %

AIM ImmunoTech (STU:HXB2) 12-1 Month Momentum % : 14.25% (As of May. 11, 2024)


View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-11), AIM ImmunoTech's 12-1 Month Momentum % is 14.25%.

The industry rank for AIM ImmunoTech's 12-1 Month Momentum % or its related term are showing as below:

STU:HXB2's 12-1 Month Momentum % is ranked better than
77.66% of 1486 companies
in the Biotechnology industry
Industry Median: -22.355 vs STU:HXB2: 14.25

Competitive Comparison of AIM ImmunoTech's 12-1 Month Momentum %

For the Biotechnology subindustry, AIM ImmunoTech's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's 12-1 Month Momentum % falls into.



AIM ImmunoTech  (STU:HXB2) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AIM ImmunoTech  (STU:HXB2) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


AIM ImmunoTech 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (STU:HXB2) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines